{"id":63319,"date":"2026-04-16T18:01:19","date_gmt":"2026-04-16T10:01:19","guid":{"rendered":"https:\/\/flcube.com\/?p=63319"},"modified":"2026-04-16T18:01:20","modified_gmt":"2026-04-16T10:01:20","slug":"gsk-acquires-35pharma-for-950-million-to-secure-best-in-class-pulmonary-arterial-hypertension-therapy-hs235","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63319","title":{"rendered":"GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235"},"content":{"rendered":"\n<p><strong>GlaxoSmithKline plc<\/strong> (GSK, <a href=\"https:\/\/www.google.com\/finance\/quote\/GSK:NYSE\">NYSE: GSK<\/a>) has completed its acquisition of <strong>35Pharma Inc.<\/strong>, a Canadian biopharmaceutical company, for <strong>USD 950 million<\/strong> in a deal initially announced in February 2026. The transaction provides GSK with <strong>HS235<\/strong>, a <strong>best-in-class therapy targeting the activin receptor signaling pathway<\/strong> for the treatment of <strong>pulmonary arterial hypertension (PAH)<\/strong>, a rare and progressive cardiovascular disease with high unmet medical need.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>GlaxoSmithKline plc (NYSE: GSK)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>35Pharma Inc. (private, Canada)<\/td><\/tr><tr><td><strong>Transaction Value<\/strong><\/td><td>USD 950 million<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>February 2026<\/td><\/tr><tr><td><strong>Closing Date<\/strong><\/td><td>April 2026<\/td><\/tr><tr><td><strong>Key Asset<\/strong><\/td><td>HS235 \u2013 best-in-class PAH therapy<\/td><\/tr><tr><td><strong>Therapeutic Target<\/strong><\/td><td>Activin receptor signaling pathway<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-asset-profile-hs235\">Asset Profile \u2013 HS235<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism of Action:<\/strong> Selective inhibitor of activin receptor signaling pathway<\/li>\n\n\n\n<li><strong>Therapeutic Indication:<\/strong> Pulmonary arterial hypertension (PAH)<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Advanced clinical development with best-in-class profile established<\/li>\n\n\n\n<li><strong>Target Validation:<\/strong> Activin signaling pathway clinically validated in PAH pathogenesis<\/li>\n\n\n\n<li><strong>Competitive Position:<\/strong> Positioned to capture significant market share in rapidly growing PAH segment<\/li>\n<\/ul>\n\n\n\n<p>HS235 represents a strategic addition to GSK&#8217;s cardiovascular portfolio, leveraging a clinically validated mechanism that addresses the underlying pathophysiology of PAH through modulation of aberrant activin signaling.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-strategic-rationale\">Market Opportunity &amp; Strategic Rationale<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-pulmonary-arterial-hypertension-landscape\">Pulmonary Arterial Hypertension Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Market Size:<\/strong> Projected to reach <strong>USD 18 billion by 2032<\/strong><\/li>\n\n\n\n<li><strong>Activin Inhibitor Market Share:<\/strong> Expected to capture <strong>50% of total PAH market<\/strong> (USD 9 billion)<\/li>\n\n\n\n<li><strong>Current Treatment Gap:<\/strong> Limited therapeutic options with suboptimal efficacy and safety profiles<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Estimated 50,000-100,000 diagnosed PAH patients globally, with significant undertreatment<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-for-glaxosmithkline\">For GlaxoSmithKline<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Expansion:<\/strong> Strengthens GSK&#8217;s position in specialty cardiovascular therapeutics<\/li>\n\n\n\n<li><strong>Rare Disease Focus:<\/strong> Aligns with GSK&#8217;s strategy to build leadership in high-value orphan indications<\/li>\n\n\n\n<li><strong>Commercial Synergies:<\/strong> Leverages existing GSK infrastructure in pulmonary and cardiovascular markets<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Significant upside from premium pricing in orphan drug segment with limited competition<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-dynamics\">Competitive Dynamics<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First-Mover Advantage:<\/strong> Early entry into activin signaling inhibitor class positions GSK ahead of potential competitors<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Strong patent protection expected to provide market exclusivity through 2040+<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Potential for accelerated approval based on compelling clinical data and unmet medical need<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-impact-amp-integration-strategy\">Financial Impact &amp; Integration Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Deal Multiples:<\/strong> Implied valuation reflects premium for best-in-class positioning in high-growth orphan indication<\/li>\n\n\n\n<li><strong>Integration Timeline:<\/strong> Immediate integration of 35Pharma team into GSK&#8217;s specialty medicines unit<\/li>\n\n\n\n<li><strong>Investment Allocation:<\/strong> Additional R&amp;D funding committed to accelerate HS235 development and regulatory submissions<\/li>\n\n\n\n<li><strong>Geographic Rollout:<\/strong> Initial focus on US and EU markets, followed by global expansion including Japan and China<\/li>\n<\/ul>\n\n\n\n<p>&#8220;This acquisition of 35Pharma and HS235 represents a strategic opportunity to address a significant unmet need in pulmonary arterial hypertension,&#8221; said Emma Walmsley, Chief Executive Officer of GSK. &#8220;With activin signaling inhibitors projected to dominate half of the $18 billion PAH market by 2032, HS235&#8217;s best-in-class profile positions us to deliver meaningful value for patients and shareholders alike.&#8221;<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding acquisition benefits, market projections, and development timelines. Actual results may differ due to risks including regulatory approvals, competitive developments, market adoption rates, and integration challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>GlaxoSmithKline plc (GSK, NYSE: GSK) has completed its acquisition of 35Pharma Inc., a Canadian biopharmaceutical&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63322,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4622,278,184,914,24],"class_list":["post-63319","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-35pharma","tag-glaxosmithkline","tag-gsk","tag-nyse-gsk","tag-rare-orphan-disease-drugs"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"GlaxoSmithKline plc (GSK, NYSE: GSK) has completed its acquisition of 35Pharma Inc., a Canadian biopharmaceutical company, for USD 950 million in a deal initially announced in February 2026. The transaction provides GSK with HS235, a best-in-class therapy targeting the activin receptor signaling pathway for the treatment of pulmonary arterial hypertension (PAH), a rare and progressive cardiovascular disease with high unmet medical need.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63319\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235\" \/>\n<meta property=\"og:description\" content=\"GlaxoSmithKline plc (GSK, NYSE: GSK) has completed its acquisition of 35Pharma Inc., a Canadian biopharmaceutical company, for USD 950 million in a deal initially announced in February 2026. The transaction provides GSK with HS235, a best-in-class therapy targeting the activin receptor signaling pathway for the treatment of pulmonary arterial hypertension (PAH), a rare and progressive cardiovascular disease with high unmet medical need.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63319\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-16T10:01:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-16T10:01:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1604.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63319#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63319\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235\",\"datePublished\":\"2026-04-16T10:01:19+00:00\",\"dateModified\":\"2026-04-16T10:01:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63319\"},\"wordCount\":494,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63319#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1604.webp\",\"keywords\":[\"35Pharma\",\"GlaxoSmithKline\",\"GSK\",\"NYSE: GSK\",\"Rare \\\/ orphan disease drugs\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63319#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63319\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63319\",\"name\":\"GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63319#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63319#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1604.webp\",\"datePublished\":\"2026-04-16T10:01:19+00:00\",\"dateModified\":\"2026-04-16T10:01:20+00:00\",\"description\":\"GlaxoSmithKline plc (GSK, NYSE: GSK) has completed its acquisition of 35Pharma Inc., a Canadian biopharmaceutical company, for USD 950 million in a deal initially announced in February 2026. The transaction provides GSK with HS235, a best-in-class therapy targeting the activin receptor signaling pathway for the treatment of pulmonary arterial hypertension (PAH), a rare and progressive cardiovascular disease with high unmet medical need.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63319#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63319\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63319#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1604.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1604.webp\",\"width\":1080,\"height\":608,\"caption\":\"GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63319#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235 - Insight, China&#039;s Pharmaceutical Industry","description":"GlaxoSmithKline plc (GSK, NYSE: GSK) has completed its acquisition of 35Pharma Inc., a Canadian biopharmaceutical company, for USD 950 million in a deal initially announced in February 2026. The transaction provides GSK with HS235, a best-in-class therapy targeting the activin receptor signaling pathway for the treatment of pulmonary arterial hypertension (PAH), a rare and progressive cardiovascular disease with high unmet medical need.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63319","og_locale":"en_US","og_type":"article","og_title":"GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235","og_description":"GlaxoSmithKline plc (GSK, NYSE: GSK) has completed its acquisition of 35Pharma Inc., a Canadian biopharmaceutical company, for USD 950 million in a deal initially announced in February 2026. The transaction provides GSK with HS235, a best-in-class therapy targeting the activin receptor signaling pathway for the treatment of pulmonary arterial hypertension (PAH), a rare and progressive cardiovascular disease with high unmet medical need.","og_url":"https:\/\/flcube.com\/?p=63319","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-16T10:01:19+00:00","article_modified_time":"2026-04-16T10:01:20+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1604.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63319#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63319"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235","datePublished":"2026-04-16T10:01:19+00:00","dateModified":"2026-04-16T10:01:20+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63319"},"wordCount":494,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63319#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1604.webp","keywords":["35Pharma","GlaxoSmithKline","GSK","NYSE: GSK","Rare \/ orphan disease drugs"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63319#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63319","url":"https:\/\/flcube.com\/?p=63319","name":"GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63319#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63319#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1604.webp","datePublished":"2026-04-16T10:01:19+00:00","dateModified":"2026-04-16T10:01:20+00:00","description":"GlaxoSmithKline plc (GSK, NYSE: GSK) has completed its acquisition of 35Pharma Inc., a Canadian biopharmaceutical company, for USD 950 million in a deal initially announced in February 2026. The transaction provides GSK with HS235, a best-in-class therapy targeting the activin receptor signaling pathway for the treatment of pulmonary arterial hypertension (PAH), a rare and progressive cardiovascular disease with high unmet medical need.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63319#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63319"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63319#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1604.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1604.webp","width":1080,"height":608,"caption":"GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63319#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"GSK Acquires 35Pharma for $950 Million to Secure Best-in-Class Pulmonary Arterial Hypertension Therapy HS235"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1604.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63319"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63319\/revisions"}],"predecessor-version":[{"id":63323,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63319\/revisions\/63323"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63322"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}